Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,674 other S bills in the 119th — cohort avg 32d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (23)
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Medicare/Medicaid
HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act S. 5037 MediKids Act S. 5244 Sustain 340B Act H.R. 10770 340B Rebate Model Delay Act
Client expense: $57,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2026 · third_quarter · Health Issues
HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act S. 5037 MediKids Act S. 5244 Sustain 340B Act H.R. 10770 340B Rebate Model Delay Act
Client expense: $57,000 · Firm income: Not reported
2026 · third_quarter · Health Issues
S. 2355 Patients Deserve Price Tags Act, Health care policy; Telehealth; U.S. Family Health Plan; H.R. 9599, Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act, S.5244, Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the future of 340B Act, 340B; H.R. 9790, Modernizing Opiod Treatment Access Act 2.0, S.4941, Modernizing Opiod Treatment Access Act 2.0, MOTAA 2.0
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
FY 2026 Appropriations for Agencies ---Administration for Strategic Preparedness and Response (ASPR) ---Centers for Disease Control and Prevention (CDC) ---Centers for Medicare and Medicaid (CMS) ---Food & Drug Administration (FDA) ---Health Resources and Services Administration (HRSA) ---National Institutes of Health (NIH) FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---CICP ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Funding for Strategic National Stockpile ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Influenza Planning & Response ---MCM PRV Reauthorization ---Pandemic Preparedness -R&D Funding for Medical Countermeasures ---Pediatric Priority Review Voucher ---Prescription Drug User Fee Act (PDUFA) VIII Implementation ---Project Bioshield ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Section 317 Immunization Program ---Vaccines and Infectious Diseases ---Vaccine Injury Compensation Program 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---H.R.9599: SECURE 340B Act ---S.5244: SUSTAIN 340B Act ---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biodefense Research, Development and Procurement Issues (Non-Funding) ---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act) ---Implementation of BIOSECURE Act ---MCM PRV Program Reauthorization ---National Defense Authorization Act 2027 ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Risky Research Review Act ---VICP Loopholes Biosimilars ---H.R.10628/S.5571: Biosimilars Access and Affordability Act ---S.1414: Expedited Access to Biosimilars Act ---S.1954: Biosimilar Red Tape Elimination Act ---Biosimilars Competition (General) ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments in New Innovation (MINI) Act Clinical Trial Data in China ---Next-Generation U.S. Clinical Development to Accelerate Cures - Legislative Discussion Draft Data Privacy ---H.R.8413: SECURE Data Act ---Clinical Trial Data in China ---Implementation of BIOSECURE Act Diagnostics and Personalized Medicine Regulation and Oversight Diversity & Inclusion ---H.R.3521: Clinical Trial Modernization Act ---Decentralized Clinical Trials Drug Evaluation and Review ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---S.3788: CLEAR Labels Act ---Advanced Manufacturing ---Compounding Pharmacies ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.2658: Medication Affordability and Patient Integrity Act Drug Pricing ---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.5391/S.2764 Protecting Patient Access to Cancer and Complex Therapies Act ---H.R.9418: Access to Innovative Treatments Act of 2026 ---S.526: Pharmacy Benefit Manager Transparency Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1954: Biosimilar Red Tape Elimination Act ---S.3014: Ensuring Timely Access to Generics ---CMMI Authority ---Ensuring Access to Generic Medications Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Implementation of ORPHAN Cures Act ---International Pricing Policies ---Tariffs Efforts to Expand the Bioeconomy & Biomanufacturing ---H.R.8930: Federal Biotechnology Workforce Assessment Act ---H.R.8938: Biotechnology Workforce Alignment Act of 2026 Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Generic Drug Entry ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.1095: Stop STALLING Act ---Generic Drug Application Review Reforms ---Incentives for Generic Entry Issues Relating to Medical Research and Animal Testing ---FDA Modernization Act 3.0 Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---Drug Benefit Design ---Most Favored Nation Drug Pricing Proposals ---Pricing and Rebates National Defense ---Medical Countermeasure Priority Review Voucher Reauthorization ---H.R.8800: National Defense Authorization Act for Fiscal Year 2027 National Security ---H.R.10568: Protecting Biological Data as Critical Infrastructure Act ---H.R.10569: Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act ---S.3741: Biosecurity Modernization and Innovation Act of 2026 ---Clinical Trial Data in China ---CMMI: GLOBE and GUARD Models ---Implementation of BIOSECURE Act ---International Pricing Policies ---Medical Countermeasure Priority Review Voucher Reauthorization ---NSC/OSTP priorities ---Nucleic acid synthesis security and biotechnology governance Opioid Crisis ---Non-Opioid Analgesics Orphan Drug Issues ---H.R.1414: Cameron's Law ---Implementation of ORPHAN Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit Pandemic Preparedness ---Drug Supply Chain Management ---R&D Funding for Medical Countermeasures ---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA) ---Supply Chain Issues Precision Medicine Initiative Rare Pediatric Disease Priority Review ---H.R.10359: Priority for Pediatric Cures Act ---S.822: Scientific EXPERT Act ---Rare Disease Pilot Program Reimbursement and Coverage of Innovative Products ---H.R.5509/S.2903:SAFE STEP Act ---S.864/H.R.6423: HELP Copays Act ---Access to Innovative Treatments ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Prior Authorization Reform ---Protected Classes ---Step Therapy ---Support of Patient Premiums and Cost-Sharing Obligations ---Value-Based Contracting and Communications ---Value-Based Purchasing (VBP) Rule Vaccines and Infectious Diseases ---H.R.5509/S.2903: SAFE STEP Act ---H.R.7352/S.4875: PASTEUR Act of 2026 ---H.R.9418: Access to Innovative Treatments Act of 2026 ---H.R.9672: Vaccine Injury Compensation Modernization Act of 2026 ---Adult Immunization ---Maternal Immunization ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Monoclonal Antibody Coverage and Utilization ---Senate Discussion Draft - Vaccine Injury Protection Act ---Vaccine and Antimicrobial Resistance Product Development and Incentives ---Vaccine Injury Compensation Program ---Vaccine Safety ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence
2026 · third_quarter · Medicare/Medicaid
FY 2026 Appropriations for Specific Issues ---Alternative Funding Programs ---Antimicrobial Resistance (General) ---CMMI: GLOBE and GUARD Models ---Drug Pricing ---Pandemic Preparedness - R&D Funding for Medical Countermeasures ---Vaccines and Infectious Diseases 340B Drug Discount Program ---H.R.5256: 340B ACCESS Act ---H.R.9504: Tax Exempt Hospital Transparency Act ---H.R.9599: SECURE 340B Act ---S.5244: SUSTAIN 340B Act ---Program Implementation & Oversight ---Rebate Models Accelerated Approval Artificial Intelligence (AI) Alternative Funding Programs Biosimilars ---H.R.10628/S.5571: Biosimilars Access and Affordability Act ---S.1954: Biosimilars Red Tape Elimination Act ---Interchangeability and Pharmacy Substitution Cell & Gene Therapy ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.7871/S.1637: MVP Act Clinical Trial Data in China Data Privacy ---H.R.8413: SECURE Data Act Diversity & Inclusion ---Decentralized Clinical Trials Drug Evaluation and Review ---FDA Hiring Flexibility Drug Importation Drug Manufacturing, Quality & Distribution ---Advanced Manufacturing ---Compounded Medicines ---Drug Shortages ---Supply Chain Integrity and Traceability Drug Patenting ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---Patent Thickets ---Restrictions on Intellectual Property Rights Drug Pricing ---H.R.946: ORPHAN Cures Act ---H.R.1492/S.832: Ensuring Pathways to Innovative Cures (EPIC) Act ---H.R.1672: Maintaining Investments and New Innovation (MINI) Act ---H.R.6166: Lowering Drug Costs for American Families Act ---S.526: Pharmacy Benefit Manager Transparency Act ---S.527: Prescription Pricing for the People Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---CMMI Authority ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Most Favored Nation Drug Pricing Proposals ---Patient Cost-Sharing and Implementation ---PBM Reform Foreign Drug Data Protection Laws ---Regulatory Harmonization Medicaid ---S.526: Pharmacy Benefit Manager Transparency Act ---Alternative Payment Arrangements for Gene Therapies ---CMMI (GENEROUS Model) ---Drug Benefit Design ---Medicaid Drug Rebate Program ---Most Favored Nation in Medicaid ---Pricing and Rebates ---Value-Based Purchasing (VBP) Rule Opioid Crisis ---Coverage and Reimbursement Orphan Drug Issues ---H.R.1414: Cameron's Law ---H.R.6166: Lowering Drug Costs for American Families Act ---H.R.10359: Priority for Pediatric Cures Act ---Implementation of the Inflation Reduction Act (IRA) of 2022 ---Orphan Drug Tax Credit Pandemic Preparedness ---Drug Supply Chain Management ---Medical Countermeasure Priority Review Voucher Reauthorization ---Monoclonal Antibody Coverage and Utilization ---R&D Funding for Medical Countermeasures ---WHO Pandemic Preparedness Accord Reimbursement and Coverage of Innovative Products ---H.R.6166: Lowering Drug Costs for American Families Act ---S.864/H.R.6423: HELP Copays Act ---CMMI Authority ---Medicare Part B Physician-Administered Products ---National Coverage Determination ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Support of Patient Premiums and Cost-Sharing Obligations Vaccines and Infectious Diseases ---Adult Immunization ---Countermeasures Injury Compensation Program ---Maternal Immunization ---MCM Manufacturing & Capacity ---Medical Countermeasure Priority Review Voucher Reauthorization ---Vaccine Injury Compensation Program ---Vaccine Safety and Quality ---Vaccine Safety Net and Vaccine Infrastructure ---Value of Vaccines and Vaccine Confidence
| Democratic |
| WI |
| Tim Kaine | Democratic | VA |
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
Client expense: $2,560,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
Client expense: $2,560,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · third_quarter · Health Issues
Erica Schwartz, of Florida, to be Director of the Centers for Disease Control and Prevention, vice Susan Monarez. (PN932) Heidi Overton, of New Mexico, to be Commissioner of Food and Drugs, Department of Health and Human Services, vice Martin Makary. (PN1273-17) Rural Obstetrics Readiness Act (S. 380/H.R. 1254) Jeanette Acosta Invest in Womens Health Act of 2026 (S.5546) Chloe Cole Act (H.R. 7651/H.R. 5843) State Offices of Womens Health Support and Expansion Act (H.R. 9842) Access to Claims Data Act (H.R. 4331) Patients First Act of 2026 (H.R. 9693) A Medicaid fix bill (not introduced yet) Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency (SECURE) in 340B Act (H.R. 9599) SUSTAIN 340B Act (S. 5244) Safety Net Provider Drug Pricing Protection Act (not introduced yet) Medicaid streamline enrollment bill (not introduced) Protecting Taxpayers from Health Care Fraudsters Act (H.R. ____) Health Information Privacy Reform Act (S. 3097)
Client expense: $308,925 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
H.R. 5256: 340B ACCESS Act; all provisions H.R. 9599: SECURE 340B Act; all provisions S. 5244: SUSTAIN 340B Act; all provisions (Discussion Draft) 340B for Patients Act; all provisions General discussions related to Drug cost and pricing policy issues General discussions related to Healthcare supply chain policy issues General discussions related to 340B Drug Pricing Program policy issues
Client expense: $730,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
2026 · third_quarter · Health Issues
H.R. 4581 / S.2372, 340B PATIENTS Act, all provisions; H.R. 5256, 340B Access Act, all provisions; DRAFT, 340B Drug Pricing Integrity and Affordability for Patients Act, all provisions; H.R. 9599, Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act), all provisions; S. 5244, Supporting Underserved and Strengthening Transparency Accountability and Integrity Now (SUSTAIN) Act, all provisions; H.R. 3178 / S. 1600, The Save Healthcare Workers Act, all provisions; H.R. 929 / S. 266, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, all provisions; H.R. 1585 / S. 709, Conrad State 30 and Physician Access Reauthorization Act, all provisions; S. 1874, Title VIII Nursing Workforce Reauthorization Act, all provisions; S. 2169 / H.R. 9908, Rural Hospital Cybersecurity Enhancement Act, all provisions; H.R. 5283 / S. 2759, Healthcare Workforce Resilience Act, all provisions; S. 3315, Health Care Cybersecurity and Resiliency Act of 2025, all provisions; DRAFT, Health Care Cybersecurity and Resiliency Act of 2026, all provisions; S. 2355 / H.R. 5582, Patients Deserve Price Tags Act, all provisions; H.R. 7961, Physicians and the Healthcare Workforce Act, all provisions; S. 3435 / H.R. 6607, The Future Advancement of Academic Nursing, all provisions; DRAFT, Issues pertaining to medical debt; S. 4568 / H.R. 8691, Nursing is a Professional Degree Act, all provisions; S.J. Res 196, A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Education relating to "Reimagining and Improving Student Education-Federal Student Loan Program Final Regulations", all provisions; H.R. 6718, Professional Student Degree Act, all provisions; H.R. 9393, Lower Costs More Transparency Act of 2026, all provisions; S.4252, WIPP Economic Assistance Assurance Act of 2026, all provisions; S.3364, Fast Track Healthcare Apprenticeships Act, all provisions; H.R. 8726, the Protecting Authority and Restoring Tools Necessary for Enforcement by Regulatory States Act of 2026 PARTNERS Act, all provisions; H.R. 5629, To provide that the final rule of the Department of Health and Human Services titled Medications for the Treatment of Opioid Use Disorder, except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect, all provisions; S. 4027, Healthy Competition for Better Care Act, all provisions; S. 1482, National Nursing Workforce Center, all provisions; S. 4637, Physician Workforce Optimization Act, all provisions; H.R. 9390, Prices on the Wall Act of 2026, all provisions; H.R. 9645, Health Care Price Certainty for All Americans Act, all provisions; S. 380 / H.R. 1254, Rural Obstetrics Readiness Act, all provisions; H.R. 9996, No Surprise Bills for New Moms Act, all provisions; H.R. 9862, The Responsible Artificial Intelligence for Veterans Act of 2026, all provisions; S. 5462, Frontier Community Health Integration Project Extension Act (FCHIP Extension Act), all provisions; H.R. 10440, REACH Act, all provisions; DRAFT, Graduate Medical Education (GME), Issues pertaining to graduate medical education (GME) reforms; H.R. 2936 / S. 1974, The Addressing Boarding and Crowding in the Emergency Department (ABC-ED) Act, all provisions; H. Res 1519, National Physician Suicide Awareness Day Resolution, Supporting the designation of September 17, 2026, as "National Physician Suicide Awareness Day" to raise awareness of, and promote a national discussion about, physician suicide and to reduce the stigma of mental health conditions, and for other purposes; H.R. 5439 / S. 2834, Medically Tailored Home-Delivered Meals Program Pilot Act, all provisions S. 4927, Rural Hospital Emergency Room Guarantee Act, all provisions; Health Resources and Services Administration (HRSA), Issues pertaining to the 340B Rebate Model Pilot Program and information collection request; Consumer Product Safety Commission, Issues pertaining to hospital and health system priorities for the 2027 and 2028 fiscal years; Food & Drug Administration, Issues pertaining to regulation of non-device software such as digital health technology, AI, wellness applications and wearable devices; Enhanced Premium Tax Credits, Extension of Enhanced Premium Tax Credits; Rural Health Care Access, Issues to protect access to rural health care; 340B Program, Issues pertaining to protecting 340B Program, including 340B Rebate Model Pilot Program; Maternal and Child Health, Access to maternal and child health care and addressing related workforce shortages, conditions of participation (COP), funding priorities; Behavioral Health, Issues related to expanding access to care and reducing regulatory barriers; Workforce, Issues pertaining to workforce development programs, supporting health care workforce and physician shortages, loan repayment programs for providers in rural and underserved areas, Graduate Medical Education program; Health Plan Accountability, Issues specific to prior authorization, patient access to care, adequate provider networks, inappropriate denials, reducing account receivables, prompt pay, white-bagging and brown-bagging policies; Health Care Resiliency & Preparedness, Issues pertaining to natural disasters, strengthen health care cybersecurity, cybersecurity workforce, and securing drug supply chains, hospital preparedness program, PAHPA reauthorization; Healthcare Price Transparency, Issues related to health care price transparency; Affordability, Issues and policy solutions pertaining to health care affordability and rising costs of health care; Tax-exempt status, Issues pertaining to not-for-profit hospitals' tax exempt status and tax-exempt private activity bonds; Immigration, Proposed H1-B Visa Program changes and impact to health care workforce; AI in Healthcare, Issues pertaining to the use of AI in healthcare and cybersecurity needs; Professional Degree Program Changes, Issues pertaining to new student loan borrowing limits and professional degree programs changes; Drug Prices, Issues pertaining to lowering drug prices, securing drug supply chain, and transparency; Rural Health Transformation Fund, Issues pertaining to implementation of the Rural Health Transformation program; Hospital Mergers & Acquisitions, Issues pertaining to hospital mergers and acquisitions; No Surprises Act, Issues pertaining to No Suprises Act reforms; Health Outcomes, Issues pertaining to prevention, nutrition, and improving health outcomes.
Client expense: $3,840,000 · Firm income: Not reported
Government targets: Consumer Product Safety Commission (CPSC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
2026 · third_quarter · Health Issues
S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Peptides/counterfeiting policy issues Controlled substances policy issues Generics/devices policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B Rebate Model Pilot Program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First
Client expense: $1,530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2026 · third_quarter · Health Issues
H.R. 9599, SECURE 340B Act S. 5244, SUSTAIN 340B Act Notice Regarding 340B Rebate Model Pilot Program (FR Doc. 2026-15633)(91 FR 48883) issued on 08/03/2026 by the Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA); 340B rebate model related issues Hospital Outpatient Prospective Payment-Notice of Proposed Rulemaking with Comment Period (NPRM) (CMS-1850-P), 2027 Hospital Outpatient Prospective Payment System (OPPS) and Quality Reporting Program and Ambulatory Surgical Center (ASC) Quality Program related issues
Client expense: $250,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to 340B rebate model Issues related to 340B for Patients Act Senate discussion draft H.R. 9599, SECURE 340B Act (Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act) S. 5244, SUSTAIN 340B Act (Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act) H.R. 5469 & S. 2858, Stillbirth Health Improvement and Education (SHINE) for Autumn Act H.R. 6238 & S. 3254, NIH IMPROVE (Implementing a Maternal health and Pregnancy Outcomes Vision for Everyone) Act
Client expense: Not reported · Firm income: $63,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program H.R.9504: Tax Exempt Hospital Transparency Act 340B Program Implementation & Oversight H.R. 9599 - SECURE 340B Act S. 5244 - SUSTAIN 340B Act Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies Most Favored Nation (MFN) policy Clinical trial data in China S.3788: CLEAR Labels Act S. 4784/H.R. 8800: National Defense Authorization Act for Fiscal Year 2027
Client expense: $840,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2026 · third_quarter · Health Issues
340b drug pricing program. Health care workforce. Health care supply chain. Health care drug shortages. H.R. 9599 - SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements of Efficiency in 340B Act. S. 5244 - SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Health issues impacting academic medical systems. Issues related to NIH research. 340B Pharmaceutical pricing issues. S.2355 - Patients Deserve Price Tags Act H.R. 9393 - Lower Costs More Transparency Act. H.R. 9599 SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act. S. 5244 SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
340B pharmaceutical pricing issues. Healthcare workforce issues. Healthcare affordability. H.R. 9599 SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act. S. 5244 SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
340B pharmaceutical pricing issues. Healthcare workforce issues. Healthcare affordability. H.R. 9393 - Lower Costs More Transparency Act. H.R. 9390 - Prices on the Walls Act. H.R. 9599 SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act. S. 5244 SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to 340B rebate model Issues related to 340B for Patients Act Senate discussion draft (no bill number) H.R. 9599, SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act). S. 5244 SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act. H.R. 5582 & S. 2355, Patients Deserve Price Tags Act H.R. 9390, Prices on the Wall Act of 2026
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
340B reform. S.2355/H.R.5582 - Patients Deserve Price Tags Act. H.R. 9390 - Prices on the Wall Act of 2026. H.R. 9393 - Lower Costs More Transparency Act. H.R. 9599 SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act. S. 5244 SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Affordable prescription drugs. Health care privacy. Health care workforce and staffing. Issues related to children's medical care. Issues related to non-profit hospital practices. H.R. 247 - Healthcare Affordability Act. Patients Deserve Price Tags Act. H.R. 9390 - Prices on the Wall Act of 2026. H.R. 9393 - Lower Costs More Transparency Act. H.R. 9599 SECURE 340B Act - Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act. S. 5244 SUSTAIN 340B Act - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
NACHC lobbies for Teaching Health Center Graduate Medical Education; Nurse Corps; National Health Service Corps; 340B Drug Discount Program; Community Health Center Program; Behavioral Health; Telehealth; and Nutrition policies. This includes the Community Health Center Drug Pricing Protection Act (H.R.7391), SUSTAIN 340B Act (S. 5244), and SECURE 340B Act (H.R. 9599).
Client expense: $194,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
2026 · third_quarter · Pharmacy
Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft SECURE 340B Act, HR 9599 SUSTAIN 340B Act, S. 5244 Comments on Senate Finance Committee RFI on drug pricing
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R. 1, One Big Beautiful Bill Act, implementation and patient access issues. S. 1816/H.R. 3514, Improving Seniors' Timely Access to Care Act. S. 1717/H.R. 5343, Ensuring Patient Access to Critical Breakthrough Products Act. H.R. 3521/S. 4440, Clinical Trial Modernization Act. S. 2903/H.R. 5509, Safe Step Act. FY 2027 Labor, HHS, Education appropriations for programs affecting people with chronic diseases and disabilities. S. 494/ H.R.1189 National Plan for Epilepsy Act Senate Finance Committee RFI on Drug Pricing and Health Coverage H.R. 9599 SECURE 340B Act Discussion Draft - 340B Drug Pricing Integrity and Affordability for Patients Act S. 5244 SUSTAIN 340B Act H.R.7352/S. 4875 PASTEUR Act S.3267/H.R. 6130 ASAP Act
Client expense: $21,227 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issue: Educate Congress on how the 340B Drug Pricing Program helps safety-net providers fulfill their missions and care for patients and communities. Support measures to preserve and strengthen the 340B Drug Pricing Program. Support measures to prevent pharmacy benefit managers and commercial insurers from imposing discriminatory reimbursement policies on 340B covered entities. Support codification of covered entities ability to use contract pharmacies. Support protections against manufacturer-imposed claims submission requirements. 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act) Issue: Oppose efforts to restrict the scope of the 340B program and transition 340B into a rebate model. Oppose additional reporting requirements for 340B hospitals. Oppose additional restrictions on 340B patient definition. Oppose numeric and geographic limits on covered entities use of contract pharmacy arrangements. Oppose restrictions on child site eligibility based on a site's proportion of charity care or Medicaid outpatient services. S.5244 - Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act (SUSTAIN 340B Act) Issue: Support codifying covered entities ability to use an unlimited network of contract pharmacies to deliver 340B-acquired drugs to patients. Support protecting 340B covered entities against discrimination by pharmacy benefit managers and payers. Support legislatively codifying Congress intent for the 340B program. Support a moratorium on the Department of Health and Human Services 340B Rebate Model Pilot Program. Oppose additional restrictions on 340B patient definition. Oppose additional reporting requirements for 340B hospitals. H.R.9599 - Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act) Issue: Support codifying covered entities ability to use an unlimited network of contract pharmacies to deliver 340B-acquired drugs to patients. Support protecting 340B covered entities against discrimination by pharmacy benefit managers and payers. Support a moratorium on the Department of Health and Human Services 340B Rebate Model Pilot Program. Oppose additional restrictions on 340B patient definition. Oppose additional reporting requirements for 340B hospitals. Oppose restrictions on child site eligibility based on the social vulnerability score or payer mix. H.R.10770 - 340B Rebate Model Delay Act Issue: Delay implementation of the 340B Rebate Model Pilot Program. Educate lawmakers about the administrative burden such a model would impose on covered entities. Issue: Oppose shift in 340B program administration from Health Resources & Services Administration (HRSA) to Centers for Medicare and Medicaid Services (CMS). Oppose Outpatient Prospective Payment System (OPPS) Medicare Part B reimbursement reduction for 340B-acquired drugs from average sales price (ASP) plus 6 percent to ASP minus 33.4 percent. Issue: Support policies to ensure access to robust and comprehensive coverage. Oppose insurance plans that do not meet Affordable Care Act (ACA) requirements, provide adequate cost-sharing protections, or a sufficiently robust provider network. Support an extension of the enhanced premium tax credits (EPTCs) provided by the American Rescue Plan Act, or other policies to reduce premium payments, maintain enrollment, and reduce the uncompensated care burden on academic health systems. Support affordable and increased access to state Affordable Care Act (ACA) marketplace exchanges. Support policies that lower enrollees private insurance costs. Issue: Support policies to improve maternal health outcomes through expanded Medicaid coverage, enhanced data collection, and improved access to behavioral health care during the perinatal period. Issue: Educate Congress and the administration on the medical education and training continuum, higher education accreditation, the annual residency Match, and the role of the National Resident Matching Program (NRMP) in medical education and residency. Issue: Provide guidance on the implementation of the No Surprises Act (P.L.116-260). Issue: Educate Congress and the administration on the role of academic medicine in the provision of mental and behavioral health care, including initiatives to respond to the opioid epidemic. Support policies to strengthen the behavioral health workforce, promote the uptake of integrated behavioral health models, advance mental health research, and ensure access to coverage and care. Issue: Educate Congress about the financial challenges facing academic health systems, academic medical centers, teaching hospitals, and affiliated faculty physicians, including reimbursement challenges, workforce challenges, inflation, and others. Issue: Educate Congress about the role of academic health systems, academic medical centers, teaching hospitals, medical schools, and affiliated faculty physicians play in providing care to all communities, including rural and underserved populations. Issue: Support reauthorization of the Childrens Hospitals Graduate Medical Education (CHGME) program. Issue: Support reauthorization of the National Health Service Corps (NHSC). Issue: Urge full staffing and funding for health, public health, and research agencies. Issue: Educate Congress and the administration about medical education as it relates to nutrition, hunger, and health; reproductive health; substance use disorders; medication assisted treatment for opioid use disorders; health care for people with disabilities; menopause and womens health; and maternal health. Issue: Educate Congress on resident expectations related to clinical practice and oppose so-called physician service mandates. H.R.6468 - Rural Residency Planning and Development Act of 2025 Issue: Support codification of the Health Resources & Services Administration (HRSA) rural residency planning and development program. Issue: Support providing discretionary funds for rural teaching hospitals to expand their residency programs. Issue: Encourage changes to Health Resources & Services Administration (HRSA) financial aid programs as a result of Free Application for Federal Student Aid (FAFSA) updates. Issue: Educate Congress on the use of artificial intelligence (AI) in academic medicine. H.R.4262/S.4110 - Educating Medical Professionals and Optimizing Workforce Efficiency and Readiness (EMPOWER) for Health Act Issue: Support reauthorization of the Health Resources & Services Administration (HRSA) Title VII health professions programs. H.R.3593/S.1874 - Title VIII Nursing Workforce Reauthorization Act of 2025 Issue: Support reauthorization of the Health Resources & Services Administration (HRSA) Title VIII nursing workforce development programs. H.R.5428 - Medical Student Education Authorization Act Issue: Support long-term authorization for the Title VII Medical Student Education program, which provides grants to public institutions of higher education to expand or support graduate education for physicians, focusing on institutions in states with the most severe primary care provider shortage. H.Res.1589 - Expressing support for the designation of October 1 as National Latino and Latina Physician Day. Issue: Support the designation of October 1 as National Latino and Latina Physician Day. S.331 - HALT Fentanyl Act Issue: Educate Congress on research and schedule I substances. Issue: Support the US Preventive Services Task Force. Issue: Support oversight regarding changes to pediatric vaccine schedule. Issue: Provide comments on the Make America Healthy Again (MAHA) strategy. S.1941 - Cure Hepatitis C Act of 2025 Issue: Support funding to expand access to rapid screening, treatment, and services to support hepatitis C elimination. P.L.119-60 - National Defense Authorization Act for Fiscal Year 2026 H.R.3838 - Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026 S.1071 - National Defense Authorization Act for Fiscal Year 2026 Issue: Support robust medical staffing for the military health system and provisions that strengthen the military medical workforce. Issue: Oppose CDC website changes related to autism and vaccinations. Issue: Educate lawmakers about health workforce patterns including primary care.
Client expense: $431,446 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Office of Science & Technology Policy (OSTP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2026 · third_quarter · Health Issues
Section 340B Drug Pricing Program, including H.R. 9599 (SECURE 340B Act), all provisions S. 5244 (SUSTAIN 340B Act), all provisions Sickle cell disease research funding generally Drug pricing reforms generally Mental and behavioral health legislation generally H.R. 2107 (Children's Hospital GME Support Reauthorization Act of 2025), all provisions Site neutral payments to providers generally Federal telehealth policy generally
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R. 5582 & S. 2355, Patients Deserve Price Tags Act Issues related to 340B rebate model Issues related to 340B for Patients Act Senate discussion draft (no bill number) H.R. 9599, SECURE 340B Act (Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act) S. 5244, SUSTAIN 340B Act (Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B Act) Issues related to pediatric research/CHILDREN's Act (draft legislation) H.R. 5469 & S. 2858, Stillbirth Health Improvement and Education (SHINE) for Autumn Act H.R. 6238 & S. 3254, NIH IMPROVE (Implementing a Maternal health and Pregnancy Outcomes Vision for Everyone) Act H.R. 9390, Prices on the Wall Act of 2026 H.R. 3762 & S. 1834, Supporting Healthy Moms and Babies Act Issues related to spina bifida/folic acid fortification Issues related to pediatric workforce and loan repayment H.R. 8271, ICU Bed Act
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
Support for the 340B program, access for children's hospitals; SUSTAIN 340B Act (S.5244), support for provisions related to contract pharmacy, HRSA rebate program, patient definition and manufacturer requirements
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Track general healthcare agenda impacting provider organizations. H.R.9504 - Tax Exempt Hospital Transparency Act 340B Drug Pricing H.R.9599 - SECURE 340B Act S.5244 - SUSTAIN 340B Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to the 340B Drug Pricing program S. 5244, SUSTAIN 340B Act H.R. 9599 SECURE 340B Act Issues related to hospital closures issues related to health care workforce Issues related to hospital cybersecurity H.R. 9908, Rural Hospital Cybersecurity Enhancement Act S.3315 Health Care Cybersecurity and Resiliency Act of 2026 S.5443, Health Infrastructure Security and Accountability Act
Client expense: $470,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2026 · third_quarter · Health Issues
340B OPPS issues, health care workforce, health care affordability, AI, health care supply chain, prior authorization, health insurance, The 340B Drug Pricing Integrity and Affordability for Patients Act, The SECURE 340B Act(H.R. 9599),The SUSTAIN Act (S.5244).
Client expense: $180,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues pertaining to the 340B Drug Discount Program - H.R. 5256, the 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025; H.R. 9504, Tax Exempt Hospital Transparency Act; S.5244, SUSTAIN 340B Act; H.R.9599, SECURE 340B Act Step therapy reform - H.R. 5509 & S. 2903, Safe Step Act Neuroscience Drug Program - FY 2026 and FY2027 AgFDA Appropriations BRAIN Initiative - FY 2026 and FY2027 Labor-HHS Appropriations Issues related to DTC advertising regulations Headache disorders treatment and research - H.R. 5536, HEADACHE Act of 2025 Research and services for epilepsy - H.R. 1189 & S. 494, National Plan for Epilepsy Act Issues pertaining to prior authorization - HR 9396, Prior Authorization Accountability Act Issues pertaining to transparency - HR 9393, Lower Costs, More Transparency Act Issues pertaining to Pediatric Priority Review Voucher program at the FDA - H.R.10359, Priority for Pediatric Cures Act
Client expense: $130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Pharmacy
The SECURE 340B Act (H.R. 9599); The Tax-Exempt Hospital Transparency Act (H.R.9504); 340B PATIENTS Act (H.R. 4581/S.2372); The SUSTAIN 340B Act (S.5244); Senator Bill Cassidys 340B Discussion Draft bill 2027 OPPS Proposed Rule; Information Collection Request Title: 340B Rebate Model Pilot Program Application, Implementation, and Evaluation, OMB Number 0906-NEW; Manufacturer Demand for Access to in-House Pharmacy Claims Data; Lilly 340B Drug Pricing Denial; Notice Regarding 340B Rebate Model Pilot Program; Pending introduction of Reps. Bresnahan and Dingells two-year rebate model pilot ban legislation; FY27 Appropriations legislation.
Client expense: $330,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE